Product image of Moxifloxacine Double-E Pharma (Moxifloxacin) supplied by GNH India

Moxifloxacine Double-E Pharma

Active Ingredient:
Moxifloxacin
Origin:
EU

Moxifloxacine Double-E Pharma (Moxifloxacin)

Moxifloxacin, the active ingredient in Moxifloxacine Double-E Pharma, is a fluoroquinolone presented as an oral tablet for systemic use. It treats a range of serious bacterial infections in adult patients.
GNH India supplies Moxifloxacine Double-E Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Double-E Pharma Ltd

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Moxifloxacine Double-E Pharma, a fluoroquinolone antibacterial, is indicated for several bacterial infections.

  • Community‑acquired bacterial pneumonia: eradicates the causative pathogens and improves respiratory function.
  • Acute bacterial sinusitis: clears sinus infection and relieves congestion.
  • Acute bacterial exacerbation of chronic bronchitis: reduces bacterial load and eases bronchial inflammation.
  • Skin and skin structure infections: eliminates skin‑associated bacteria and promotes healing.
  • Complicated intra‑abdominal infections: provides broad‑spectrum coverage for mixed bacterial flora.

How It Works

  • Moxifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. By binding to these enzymes, it prevents the supercoiling and separation of DNA strands, leading to bacterial cell death and a bactericidal effect against susceptible organisms.

Side Effects

Moxifloxacine Double-E Pharma may cause adverse reactions.

Common Side Effects

  • Nausea: mild to moderate upset stomach.
  • Diarrhea: loose stools, usually self‑limiting.
  • Headache: transient cranial discomfort.
  • Rash: mild skin erythema or itching.

Serious or Rare Side Effects

  • Tendon rupture: sudden tendon pain or swelling, especially in the Achilles.
  • QT interval prolongation: risk of cardiac arrhythmias, monitor ECG in susceptible patients.
  • Severe allergic reactions: anaphylaxis, angioedema, or bronchospasm requiring immediate medical attention.

Precautions & Warnings

Before prescribing Moxifloxacine Double-E Pharma, clinicians should consider several safety measures.

  • Assess renal function: adjust therapy in patients with significant impairment.
  • Monitor for tendon pain: discontinue if signs of tendonitis or rupture appear.
  • Check cardiac status: avoid in patients with known prolonged QT or electrolyte disturbances.
  • Avoid use in pregnancy: insufficient data on fetal safety; consider alternatives.
  • Store at room temperature below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Moxifloxacine Double-E Pharma can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

  • Antacids containing aluminum or magnesium: markedly reduce moxifloxacin absorption.
  • Systemic corticosteroids: heightened risk of tendon rupture.
  • Warfarin: potentiates anticoagulant effect, increasing bleeding risk.

Moderate Interactions (Monitor Closely)

  • CYP450 inducers (e.g., rifampicin): may lower plasma concentrations of moxifloxacin.
  • Theophylline: can raise serum theophylline levels, risking toxicity.
  • Sulfonylurea antidiabetic agents: may require dose adjustment due to enhanced hypoglycemic effect.

Frequently Asked Questions

Moxifloxacine Double-E Pharma is a prescription fluoroquinolone indicated for community‑acquired bacterial pneumonia, acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, skin and skin‑structure infections, and complicated intra‑abdominal infections. It provides broad‑spectrum coverage against typical Gram‑positive and Gram‑negative pathogens responsible for these conditions.

Moxifloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes that control DNA supercoiling and separation during replication. Inhibiting these targets prevents bacterial DNA synthesis and transcription, leading to rapid bacterial cell death and a bactericidal effect against susceptible organisms.

The dosage of Moxifloxacine Double-E Pharma is determined by the prescribing clinician based on the specific infection, patient age, renal function, and other clinical factors. Only a qualified healthcare professional should set the dose and duration of therapy.

Safety data for moxifloxacin in pregnancy are limited, and the drug is generally avoided unless the potential benefit outweighs the risk. It is also not recommended during breastfeeding because it may pass into breast milk. Alternative agents with established safety profiles should be considered.

To request Moxifloxacine Double-E Pharma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Moxifloxacin offers a broader spectrum against Gram‑positive organisms and better activity in respiratory infections compared with older fluoroquinolones such as ciprofloxacin. It also has a once‑daily dosing schedule, which can improve adherence, but it shares class‑related warnings like tendon toxicity and QT prolongation.

Moxifloxacine Double-E Pharma tablets should be stored at room temperature below 25 °C, in the original packaging, and protected from moisture and direct sunlight. Do not store in a refrigerator or freezer.

The product is supplied as oral tablets that are taken by mouth with or without food, as directed by the prescriber. Swallow the tablet whole with an adequate amount of water; do not crush or chew unless specifically instructed.

Serious risks include tendon rupture (especially Achilles), QT interval prolongation leading to potentially life‑threatening arrhythmias, severe allergic reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Patients should be educated to report sudden tendon pain, palpitations, or signs of severe hypersensitivity immediately.

Moxifloxacine Double-E Pharma is contraindicated in patients with a known hypersensitivity to moxifloxacin or other fluoroquinolones. It should also be avoided in individuals with a history of tendon disorders related to fluoroquinolone use, uncontrolled QT prolongation, or those taking medications that significantly increase the risk of tendon injury.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Moxifloxacin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT